Search strategy and selection of clinical trial according to the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) statement for reporting systematic reviews and meta-analyses.

<p>Search strategy and selection of clinical trial according to the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) statement for reporting systematic reviews and meta-analyses.</p

Odds ratio (with 95% confidence interval) of indirect comparisons of edoxaban versus dabigatran, rivaroxaban and apixaban. Efficacy end-points. Significant comparisons are printed in bold.

<p>Odds ratio (with 95% confidence interval) of indirect comparisons of edoxaban versus dabigatran, rivaroxaban and apixaban. Efficacy end-points. Significant comparisons are printed in bold.</p

Imputed placebo analysis.

<p>Comparison of new oral anticoagulants versus imputed placebo on the risk of stroke.</p

Estimated proportion of warfarin benefit by new oral anticoagulants on the risk of stroke.

<p>Estimated proportion of warfarin benefit by new oral anticoagulants on the risk of stroke.</p

Main Characteristics of Trials Evaluating New Oral Anticoagulants for Stroke Prevention in Patients with Nonvalvular Atrial Fibrillation.

<p>D, Dabigatran; R, Rivaroxaban; A, Apixaban; E, Edoxaban; N, number of patients; AF, atrial fibrillation; TIA, transient ischemic attack, TTR = time in therapeutic range (International normalized ratio 2.0 to 3.0); CHF, congestive heart failure; DM, diabetes mellitus; HTN, hypertension; CHADS₂ indicates CHF, hypertension, age, diabetes mellitus, stroke.</p><p>*  =  Stroke or TIA only.</p

Estimated proportion of warfarin benefit by new oral anticoagulants on the risk of all-cause mortality.

<p>Estimated proportion of warfarin benefit by new oral anticoagulants on the risk of all-cause mortality.</p

Imputed placebo analysis. Comparison of new oral anticoagulants versus imputed placebo on the risk of all-cause mortality.

<p>Imputed placebo analysis. Comparison of new oral anticoagulants versus imputed placebo on the risk of all-cause mortality.</p

Odds ratio (with 95% confidence interval) of indirect comparisons of edoxaban versus dabigatran, rivaroxaban and apixaban.

<p>Safety end-points. Significant comparisons are printed in bold.</p

Average Effects of New Oral Anticoagulants Versus Warfarin.

<p>Only endpoints available in all studies are reported. NOAC  =  new oral anticoagulant drug; BID  =  twice daily; OD  =  once daily; CI  =  confidence interval; OR  =  odds ratio.</p

SBP differences between minority groups and EU participants by panethnicity and gender.

<p>Subgroup comparisons of the weighted mean difference of systolic blood pressure (BP) between minority groups and EU participants by panethnicity and gender. Diamonds denote the pooled estimates and 95% confidence intervals. SSA = Sub-Saharan Africans; SA = South Asians; EU = Europeans, “n” is the number of comparisons available for each subgroup.</p